

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Mail Stop: Amendment, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 20th day of May 2005.
s/ Rachel Potash
Rachel Potash



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
PENG CHO TANG, et al.

Serial No.: 10/648,810

Confirmation No.: 3943

Filed: August 27, 2003

For: 4-HETEROARYL-3-
HETEROARYLIDENYL-2-
INDOLINONES AND THEIR USE AS
PROTEIN KINASE INHIBITORS

Group Art Unit: 1623

Examiner: Paul V. Ward

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Response to Office Action 11 pages;
2. Transmittal Letter 1 page; and
3. Total Fee Due \$0.00 Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "V. Liptak".

Vincent P. Liptak, Ph.D.
Agent For Applicants
Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7908
Fax: (858) 678-8233



Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 20th day of May 2005.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Peng Cho Tang, et al.	Group Art Unit: 1623
Serial No.: 10/648,810	Examiner: Paul V. Ward
Confirmation No.: 3943	
Filed: August 27, 2003	
For: 4-HETEROARYL-3- HETEROARYLIDENYL-2- INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS	

Mail Stop AMENDMENT
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

In response to the Office action mailed February 22, 2005, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 9 of this paper.